IGF-I R/IGF1R Antibody (teprotumumab) [Biotin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28288B
Recombinant Monoclonal Antibody

Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Biotin
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # teprotumumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
IGF1R / CD221
Reactivity Notes
Predicted species reactivity: Mouse
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for IGF-I R/IGF1R Antibody (teprotumumab) [Biotin]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IGF-I R/IGF1R
Long Name
Insulin-like Growth Factor I Receptor
Alternate Names
CD221, IGF-1R, IGF-IR, IGF1R, IGFIR
Gene Symbol
IGF1R
Additional IGF-I R/IGF1R Products
Product Documents for IGF-I R/IGF1R Antibody (teprotumumab) [Biotin]
Product Specific Notices for IGF-I R/IGF1R Antibody (teprotumumab) [Biotin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...